


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-51 (Canceled)

52. (New) A method of treating trypanosomiasis in a mammal, which comprises administering to a mammal in need thereof an effective amount of a medicinal product comprising a plant extract comprising one or more compounds of the formula (I):



(I)

wherein R1, R2, R3, R4, R5, R6, R7 and R8 represent independently of one another:

- a hydrogen atom;
- a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;
- a halogen atom;
- halo(C₁-C₁₂)alkyl, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
- hydroxyl;
- nitro;
- cyano;
- mercapto;
- carboxylic acid;
- amide;
- amine;
- C₁-C₁₂ alkoxy, wherein an alkyl group thereof is linear, branched or cyclic,

and saturated or unsaturated;
C₁-C₁₂ alkyl ester, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated,
secondary or tertiary alkylamine, wherein an C₁-C₁₂ alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated;
secondary or tertiary alkylamide, wherein an C₁-C₁₂ alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated,
C₁-C₁₂ alkylthio, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
C₂-C₆ heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen;
a group -SO₂-NR'R" or a group -NR'-SO₂-R", in which R' and R" represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group, with the proviso that one of R₃ or R₄ is other than hydrogen;
n represents 0;
R represents a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group; and
X represents an anion, which is either an inorganic or organic anion.

53. (New) The method of claim 52, wherein R₃ represents NH₂, C₁-C₁₂ alkylamine, C₁-C₁₂ alkylamide or C₂-C₆ heterocycle comprising at least one amine group.

54. (New) The method of claim 52, wherein R₄ represents hydroxyl or C₁-C₁₂ alkoxy.

55. (New) The method of claim 52, for treating trypanosomiasis in a chronic phase or an acute phase.

56. (New) The method of claim 52, for treating Chagas' disease.

57. (New) The method of claim 52, for treating trypanosomiasis caused by *Trypanosoma brucei*.

58. (New) The method of claim 52, for treating trypanosomiasis caused by *Trypanosoma cruzi*.
59. (New) The method of claim 52, wherein the medicinal product is administered at a dose of between about 0.01 and 100 mg/kg/d of compound of formula (I).
60. (New) The method of claim 59, wherein the administered dose is between about 0.1 and 50 mg/kg/d.
61. (New) The method of claim 60, wherein the administered dose is between about 1 and 20 mg/kg/d.
62. (New) The method of claim 52, wherein the medicinal product is administered orally.
63. (New) The method of claim 52, wherein the mammal is a human.
64. (New) A method of treating trypanosomiasis in a mammal which comprises administering to a mammal in need thereof an effective amount of canthin-6-one.
65. (New) The method of claim 64, wherein from 0.2 mg to 1 g of the canthin-6-one is administered per day.

66. (New) The method of claim 64, wherein the mammal is a human.

67. (New) A method of treating trypanosomiasis in a mammal, which comprises administering to a mammal in need thereof an effective amount of a medical product comprising a plant extract comprising canthin-6-one.

68. (New) The method of claim 67, wherein the canthin-6-one is present in the form of an extract of a plant selected from the group consisting of *Ailanrhus altissima*, *Brucea antidyserterica*, *Eurycoma harmandiana*, *Peganum nigellastrum*, *Zanthoxylum elephantiasis* and *Zanthoxylum chiloperone*.

69. (New) The method of claim 68, wherein the canthin-6-one is present in the form of an extract of *Zanthoxylum chiloperone* var. *angustifolium*.

70. (New) The method of claim 67, wherein the plant extract comprising canthin-6-one is obtained by a method comprising the first steps of grinding the dried bark of a trunk of *Zanthoxylum chiloperone* var. *angustifolium*, and then treating the ground dried bark with an aqueous alkaline solution.

71. (New) The method of claim 70, wherein the plant extract comprising canthin-6-one is obtained by a method further comprising a second step comprising extracting the ground bark and aqueous alkaline solution with a chlorinated organic solvent.

72. (New) The method of claim 67, for treating trypanosomiasis in a chronic phase or an acute phase.

73. (New) The method of claim 67, for treating Chagas' disease.

74. (New) The method of claim 67, for treating trypanosomiasis caused by *Trypanosoma brucei*.

75. (New) The method of claim 67 for treating trypanosomiasis caused by *Trypanosoma cruzi*.

76. (New) The method of claim 67, wherein the medicinal product is administered at a dose of between about 0.01 and 100 mg/kg/d of compound of formula (I).

77. (New) The method of claim 76, wherein the administered dose is between about 0.1 and 50 mg/kg/d.

78. (New) The method of claim 77, wherein the administered dose is between about 1 and 20 mg/kg/d.

79. (New) The method of claim 67, wherein the medicinal product is administered orally.

80. (New) The method of claim 67, wherein the mammal is a human.